OSE reports one-year survival results from Combi-TED Phase 2 trial
The French biotechnology company published topline data for three treatment groups in a 106-patient lung-cancer study.
Event / data period:
Published: · Updated:
OSE Immunotherapeutics reported results on October 19 from Combi-TED, a FoRT-sponsored, open-label, randomized Phase 2 trial of second-line treatment for metastatic non-small-cell lung cancer. It involved 106 HLA-A2-positive patients at 19 sites in France, Italy and Spain. The three groups received Tedopi with docetaxel, Tedopi with nivolumab, or docetaxel alone.
One-year overall survival was the primary endpoint. OSE reported rates of 47% for Tedopi plus docetaxel, 46% for Tedopi plus nivolumab and 29% for docetaxel alone. The company’s topline release gives the total study population without individual group sizes or confidence intervals for these rates. Detailed results are scheduled for presentation on October 25 at ESMO in Madrid.
Data
One-year overall survival in Combi-TED
Results reported for the Combi-TED Phase 2 study in OSE’s press release dated 19 October 2026.
| Tedopi + docetaxel | 47 |
| Tedopi + nivolumab | 46 |
| Docetaxel alone | 29 |
Methodology
Company-reported one-year overall-survival percentages for the open-label randomized Phase 2 trial. No rates were calculated or adjusted. The release specifies 106 patients overall, without individual arm sizes or confidence intervals for these rates.
Updated:
Subjects and places
Subject proposals
- CancerSuggested
- Subject suggested from the title or summary: cancerwww.ose-immuno.com ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- France · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.ose-immuno.com ↗